Table 3.

RRM1 and ERCC1 Protein Levels by Clinical Characteristics

Characteristic	Protein Level
	RRM1 (n = 69)			ERCC1 (n = 65)
	Median	Range	P	Median	Range	P
Age, years			.552			.650
≥ 75.0	33.4	8.5-105.6		34.7	5.2-131.3
< 75.0	34.2	5.3-90.1		35.4	10.1-102.3
Sex			.722			.401
Male	36.1	5.3-105.6		34.4	5.2-127.6
Female	33.2	8.6-93.5		47.3	11.5-131.3
Histology			.570			.893
Adeno	36.9	5.3-105.6		39.9	5.2-131.3
Squamous	23.7	9.9-93.5		34.1	6.0-104.9
Large cell and NOS	34.1	14.7-90.1		27.9	11.5-127.6
Stage			.312			.029
IV	35.1	5.3-105.6		34.4	5.2-127.6
IIIB	27.2	14.8-36.9		69.7	51.3-131.3
Treatment			.196			.610
Gemcitabine and carboplatin	32.9	6.4-105.6		36.7	12.8-131.3
Gemcitabine	39.1	5.3-90.1		33.4	5.2-127.6
Best measurable response category by CT			.023			.402
PR	22.9	5.3-81.4		34.6	10.1-84.7
SD	39.0	8.5-105.6		34.1	5.2-131.3
PD	42.2	15.2-89.4		51.8	18.7-102.3

NOTE. Wilcoxon rank sum test (with Van der Waerden quantile normal scores) for two groups and Kruskal-Wallis test for three groups. The χ² rank test P value for associations of best response with RRM1 was < .01, and it was > .10 for best response with ERCC1.²⁷

Abbreviations: NOS, not otherwise specified; CT, computed tomography; PR, partial response; SD, stable disease; PD, progressive disease.